SK bioscience applies for emergency Covid-19 vaccine approval

신하늬 2023. 10. 20. 18:16
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

SK bioscience has applied for emergency use approval for Novavax’s updated Covid-19 vaccine.
A bird's-eye view of SK bioscience's vaccine facility in Songdo, Incheon [SK BIOSCIENCE]

SK bioscience has applied for emergency use approval for Novavax’s updated Covid-19 vaccine.

SK bioscience is the local distributor of the NVX-CoV2601 vaccine developed by Novavax, exclusively in Korea and non-exclusively in Thailand and Vietnam.

The Seongnam, Gyeonggi-based company said Friday that it submitted an application for emergency use of the updated vaccine to the Korean Ministry of Food and Drug Safety. Upon authorization, SK bioscience will supply the updated Novavax Covid-19 vaccine in Korea during the 2023-2024 winter season.

The protein-based non-mRNA vaccine is the third updated Covid vaccine to be authorized in the United States against the Omicron variant.

SK bioscience made an equity investment in Novavax to become the third-biggest shareholder of the U.S. company in August.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]

Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?